Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Over ten years overall survival in glioblastoma: A different disease?

Marton E, Giordan E, Siddi F, Curzi C, Canova G, Scarpa B, Guerriero A, Rossi S, D' Avella D, Longatti P, Feletti A.

J Neurol Sci. 2020 Jan 15;408:116518. doi: 10.1016/j.jns.2019.116518. Epub 2019 Nov 1.

PMID:
31715330
2.

Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.

Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A.

JAMA Oncol. 2017 Jun 1;3(6):784-792. doi: 10.1001/jamaoncol.2016.6020.

3.

Long-term survival after glioblastoma resection: hope despite poor prognosis factors.

Costa E, Lawson TM, Lelotte J, Fomekong E, Vaz RG, Renard L, Whenham N, Raftopoulos C.

J Neurosurg Sci. 2019 Jun;63(3):251-257. doi: 10.23736/S0390-5616.18.04180-2. Epub 2018 Jan 23.

PMID:
29363298
4.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
5.

The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.

Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D, Husband D, Shenoy A, Wong H, Jenkinson MD.

Acta Neurochir (Wien). 2016 Oct;158(10):1943-53. doi: 10.1007/s00701-016-2928-8. Epub 2016 Aug 15.

PMID:
27526690
6.

Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.

Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M; German Glioma Network.

Clin Cancer Res. 2013 Sep 15;19(18):5146-57. doi: 10.1158/1078-0432.CCR-13-0017. Epub 2013 Aug 5.

7.
8.

Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.

Gessler F, Bernstock JD, Braczynski A, Lescher S, Baumgarten P, Harter PN, Mittelbronn M, Wu T, Seifert V, Senft C.

Neurosurgery. 2019 Jan 1;84(1):190-197. doi: 10.1093/neuros/nyy049.

9.

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.

Amelot A, De Cremoux P, Quillien V, Polivka M, Adle-Biassette H, Lehmann-Che J, Fran├žoise L, Carpentier AF, George B, Mandonnet E, Froelich S.

PLoS One. 2015 Jul 9;10(7):e0130596. doi: 10.1371/journal.pone.0130596. eCollection 2015.

10.

Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients.

Ye N, Jiang N, Feng C, Wang F, Zhang H, Bai HX, Yang L, Su Y, Huang C, Wanggou S, Li X.

J Cancer. 2019 Aug 29;10(22):5536-5548. doi: 10.7150/jca.30614. eCollection 2019.

11.

[Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma].

Kamoshima Y, Motegi H, Terasaka S, Kobayashi H, Yamaguchi S, Murata J, Tanaka S, Houkin K.

No Shinkei Geka. 2012 Feb;40(2):129-35. Japanese.

PMID:
22281465
12.

Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients.

Lu J, Cowperthwaite MC, Burnett MG, Shpak M.

PLoS One. 2016 Apr 28;11(4):e0154313. doi: 10.1371/journal.pone.0154313. eCollection 2016.

13.

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55. doi: 10.3174/ajnr.A2950. Epub 2012 Feb 9.

14.
15.

Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?

Sarmiento JM, Mukherjee D, Black KL, Fan X, Hu JL, Nuno MA, Patil CG.

J Neurol Surg A Cent Eur Neurosurg. 2016 May;77(3):195-200. doi: 10.1055/s-0035-1566121. Epub 2016 Mar 2.

PMID:
26935296
16.

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.

Schiffgens S, Wilkens L, Brandes AA, Meier T, Franceschi E, Ermani M, Hartmann C, Sandalcioglu IE, Dumitru CA.

Oncotarget. 2016 Aug 23;7(34):55169-55180. doi: 10.18632/oncotarget.10465.

17.

LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.

Mock A, Geisenberger C, Orlik C, Warta R, Schwager C, Jungk C, Dutruel C, Geiselhart L, Weichenhan D, Zucknick M, Nied AK, Friauf S, Exner J, Capper D, Hartmann C, Lahrmann B, Grabe N, Debus J, von Deimling A, Popanda O, Plass C, Unterberg A, Abdollahi A, Schmezer P, Herold-Mende C.

Int J Cancer. 2016 Jul 15;139(2):424-32. doi: 10.1002/ijc.30069. Epub 2016 Mar 18.

18.

Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.

Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M, Loeffler M; German Glioma Network.

Int J Cancer. 2014 Oct 15;135(8):1822-31. doi: 10.1002/ijc.28836. Epub 2014 Mar 28.

19.

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.

Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K.

Acta Neuropathol Commun. 2016 Aug 8;4(1):79. doi: 10.1186/s40478-016-0351-2.

20.

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R.

Lancet Oncol. 2008 Jan;9(1):29-38. Epub 2007 Dec 21.

PMID:
18082451

Supplemental Content

Support Center